PharmaCyte Biotech, Inc.
PMCBNasdaqCIK 1157075HealthcareFiscal year ends Apr 30
Reports and events: 210 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1621:00 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001683168-26-007934 |
| 2026-09-1420:05 ET | 10-Q | Quarterly reportPeriod 2026-07-31 | 0001683168-26-007106 |
| 2026-07-2920:58 ET | 10-K | Annual reportPeriod 2026-04-30 | 0001683168-26-005836 |
| 2026-04-0220:19 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001683168-26-002613 |
| 2026-03-1719:49 ET | 10-Q | Quarterly reportPeriod 2026-01-31 | 0001683168-26-001917 |
| 2026-03-0910:02 ET | DEF 14A | Proxy statementPeriod 2026-03-30 | 0001683168-26-001593 |
| 2025-12-1822:04 ET | 10-Q | Quarterly reportPeriod 2025-10-31 | 0001683168-25-009259 |
| 2025-12-0522:00 ET | 8-K | 3.01 Delisting notice | 0001683168-25-008947 |
| 2025-11-1821:29 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001683168-25-008515 |
| 2025-11-1821:05 ET | 8-K/A | 9.01 Financial statements and exhibits | 0001683168-25-008512 |
| 2025-10-3120:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001683168-25-007871 |
| 2025-10-0621:08 ET | DEF 14A | Proxy statementPeriod 2025-10-30 | 0001683168-25-007435 |
| 2025-09-1520:37 ET | 10-Q | Quarterly reportPeriod 2025-07-31 | 0001683168-25-006991 |
| 2025-09-0520:05 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-25-006727 |
| 2025-08-1813:20 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-25-006274 |
| 2025-08-1121:46 ET | 10-K | Annual reportPeriod 2025-04-30 | 0001683168-25-005821 |
| 2025-04-2420:47 ET | 8-K | 5.07 Shareholder vote results | 0001683168-25-002790 |
| 2025-03-1721:22 ET | 10-Q | Quarterly reportPeriod 2025-01-31 | 0001683168-25-001669 |
| 2025-03-1020:17 ET | DEF 14A | Proxy statementPeriod 2025-04-24 | 0001683168-25-001464 |
| 2025-02-2618:57 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001683168-25-001236 |
| 2024-12-1321:01 ET | 10-Q | Quarterly reportPeriod 2024-10-31 | 0001683168-24-008709 |
| 2024-09-1700:47 ET | 10-Q | Quarterly reportPeriod 2024-07-31 | 0001683168-24-006441 |
| 2024-08-1320:37 ET | 10-K | Annual reportPeriod 2024-04-30 | 0001683168-24-005575 |
| 2024-05-3020:05 ET | SC 13D | Ownership report, active investor | 0001683168-24-003883 |
| 2024-05-2320:40 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-24-003796 |
| 2024-05-0120:05 ET | 8-K | 5.07 Shareholder vote results | 0001683168-24-002881 |
| 2024-03-2720:06 ET | DEF 14A | Proxy statementPeriod 2024-04-29 | 0001683168-24-001762 |
| 2024-03-1820:02 ET | 10-Q | Quarterly reportPeriod 2024-01-31 | 0001683168-24-001525 |
| 2023-12-1522:25 ET | 10-Q | Quarterly reportPeriod 2023-10-31 | 0001683168-23-008889 |
| 2023-11-2421:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001683168-23-008446 |
| 2023-11-2221:00 ET | SC 13D | Ownership report, active investor | 0001683168-23-008419 |
| 2023-11-1601:45 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-23-008204 |
| 2023-11-0922:25 ET | 8-K | 4.01 Change of auditor | 0001683168-23-007830 |
| 2023-09-1810:04 ET | 10-Q | Quarterly reportPeriod 2023-07-31 | 0001683168-23-006505 |
| 2023-09-0720:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001683168-23-006331 |
| 2023-08-0420:01 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001683168-23-005293 |
| 2023-07-3121:18 ET | 10-K | Annual reportPeriod 2023-04-30 | 0001683168-23-005175 |
| 2023-07-3120:42 ET | DEF 14A | Proxy statementPeriod 2023-08-31 | 0001683168-23-005167 |
| 2023-07-1923:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-23-004985 |
| 2023-06-1621:22 ET | SC 13D/A | Ownership report, active investor, amended | 0000921895-23-001535 |
| 2023-06-0520:05 ET | DEF 14A | Proxy statementPeriod 2023-06-05 | 0001683168-23-003905 |
| 2023-05-1220:22 ET | SC 13D/A | Ownership report, active investor, amended | 0000921895-23-001173 |
| 2023-05-1112:30 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-23-003169 |
| 2023-03-1620:42 ET | 10-Q | Quarterly reportPeriod 2023-01-31 | 0001683168-23-001559 |
| 2023-02-0214:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-23-000500 |
| 2022-12-3021:05 ET | 8-K | 5.07 Shareholder vote results | 0001683168-22-008705 |
| 2022-12-1422:19 ET | 10-Q | Quarterly reportPeriod 2022-10-31 | 0001683168-22-008428 |
| 2022-11-2513:08 ET | DEF 14A | Proxy statementPeriod 2022-12-28 | 0001683168-22-008032 |
| 2022-11-1821:01 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001683168-22-007894 |
| 2022-11-0722:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001683168-22-007359 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:05 ET. Listed shows no prices and gives no investment advice.